Recurrent human papillomavirus infection detected with the Hybrid Capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: A longitudinal study of 3,091 women

International Journal of Cancer

Volumn 102, Issue 5, 2002, Pages 519-525

  Bory, Jean Paul ^a   Cucherousset, Joël ^a   Lorenzato, Marianne ^a   Gabriel, René ^a   Quereux, Christian ^a   Birembaut, Philippe ^a   Clavel, Christine ^a  

^a REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

Cervical intraepithelial neoplasia; Cytologic screening; Human papillomavirus; Hybrid capture

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; COLPOSCOPY; DISEASE COURSE; FEMALE; FRANCE; HISTOPATHOLOGY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; POPULATION RISK; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION; RELIABILITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERUS BIOPSY; VIRUS DIAGNOSIS; VIRUS LOAD; WART VIRUS;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; COLPOSCOPY; FEMALE; HUMANS; LONGITUDINAL STUDIES; PAPILLOMAVIRUS INFECTIONS; RECURRENCE; REPRODUCIBILITY OF RESULTS; RISK; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIRAL LOAD;

EID: 0037058719     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10735     Document Type: Article

References (36)

1. Bosch F, Lorincz A., Munoz N, Meijer CJLM, Shah KV. The causal relation between Human Papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
2. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: Relative risk association of 15 common anogenital types. Obstet Gynecol 1992;79:328-37.
3. Zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 1994;186:131-56.
4. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
5. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Peevonen J, Beckmann AM, De Rouen TA, Galloway DA, Vernon D, Kiviat NB. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
6. Gaarenstroom KN, Melkert P, Walboomers JMM, Van den Brule AJ, Van Bommel PF, Meijer CJ, Voorhorst FJ, Kenemans P, Helmerhorst TJ. Human papillomavirus DNA genotypes: Prognostic factors for progression of cervical intraepithelial neoplasia. Int J Gynecol Cancer 1994;4:73-8.
7. Cole HM. Human papillomavirus DNA testing in the management of cervical neoplasia. JAMA 1993;270:2975-81.
8. Cox JT, Lorincz AT. Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995;172:946-54.
9. Manos MM, Kinney WK, Hurley LB, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger J., McIntosh KM, Pawlick GF, Hiatt RA. Identifying women with cervical neoplasia using Human Papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999;28:1605-10.
10. Meijer CJLM, Helmerhorst TJM, Rozendaal L, Van Der Linden JC., Voorhorst FJ, Walboomers JMM. HPV typing and testing in gynaegological pathology: Has the time come? Histopathology 1998;33:83-6.
11. Richart RM, Wright TC. Controversies in the management of low grade cervical intraepithelial neoplasia. Cancer 1993;71:1413-21.
12. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-299.
13. The Atypical Squamous Cells of Undetermined Significance/Low Grage Squamous Intraepithelial Lesions Study (ALTS) Group. Human papillomavirus testing for triage of women with cytological evidence of low grade squamous intraepithelial lesions: Baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397-402.
14. Lorincz AT. Hybrid Capture method for detection of human papillomavirus DNA in clinical specimens. Papillomavirus Rep 1996;7:1-5.
15. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human papillomavirus testing in primary screening for the detection of highgrade cervical lesions: A study of 7932 women. Br J Cancer 2001;89:1616-1623.
16. Cuzick J, Beverly E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P. HPV testing in primary screening of older women. Br J Cancer 1999;81:554-558.
17. Ratnam S, Franco EL, Ferenczy A. Human Papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000;9:945-51.
18. Riethmuller D, Gay C, Bertrand X, Bettinger D, Schaal JP, Carbillet JP, Lassabe C, Arveux P, Seilles E, Mougin C. Genital Human Papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. Diagn Mol Pathol 1999;8:157-64.
19. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, Alfao M, Hutchinson M, Morales J, Greenberg MD, Lorincz AT. HPV DNA testing in cervical cancer screening: Results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.
20. Ho GYF, Bierman R., Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
21. Ho GYF, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;187:1365-71.
22. Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Rise E, Van Der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study. Lancet 1999;354:20-5.
23. Remmink AJ, Walboomers JMM, Helmerhorst TJM, Voorhorst FJ, Rozendaal L, Risse EK, Meijer CJ, Kenemans P. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. Int J Cancer 1995;61:306-11.
24. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106-3114.
25. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer 1994;69:167-17.
26. Josefsson AM, Magnusson P, Ylitalo N, Sorensen P, Qwarforth- Tubbin P, Andersen PK, Melbye M. Adami HO, Gyllenstein UB. Viral load of human papillomavirus 16 as a determinant for development of cervical carcinoma in situ: A nested case-control study. Lancet 2000;355:2189-93.
27. Ylitalo N, Sorensen P, Josefsson AM, Magnusson PK, Andersen PK, Ponten J, Adami HO, Gyllenstein UB, Melbye M. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study. Lancet 2000;355:2194-8.
28. Van Duin M, Snujders PJ, Schrijnamakers HF, Voorhorst FJ, Rozendaal L, Nobbenhuis MA, Van Den Brule AJ, Verheijen RH, Helerhorst TJ, Meijer CJ. Human Papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/III and viral clearance. Int J Cancer 2002;98:590-5.
29. Wright TC, Jr, Lorincz A, Farris DG, Richart RM, Ferenczy A, Mielzynska I, Borgatta I. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol 1998;178:862-6.
30. Liaw KL, Glass AG, Manos MM, Greer CE, Scott DR, Sherman M, Burk RD, Kurman RJ, Wacholder S, Rush BB, Cadell DM, Lawler P, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous epithelial lesions. J Natl Cancer Inst 1999;91:954-60.
31. Rozendaal L, Walboomers JMM, Van der Linden JC, Voorhorst FJ, Kenemans P, Helmerhorst TJ, Van Vallegoijen M, Meijer CJ. PCR- based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996;68:766-9.
32. Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, Van der Linden JC, Runsinkl AP, De Schipper FA, Meijer CJ. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 2001;85:398-404.
33. Villa LL, Sichero L, Rahal P, Ruiz A. Molecular variants analysis of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 2000;81:2959-68.
34. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, Hallmans G, Dillner J. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-8.
35. Monsonego J, Autillo-Touati A, Bergeron C, Dachez R, Liaras J, Saurel J, Zerat L, Chatelain P, Mottot C. Liquid-based cytology for primary cervical cancer screening: A multi-centre study. Br J Cancer 2001;84:360-366.
36. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, Rohan TE. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180:1415-1423.